Phibro Animal Health Corporation (NASDAQ:PAHC) Receives $37.50 Consensus Target Price from Brokerages

Phibro Animal Health Corporation (NASDAQ:PAHC) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $37.50.

Several brokerages recently issued reports on PAHC. Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a report on Friday, February 6th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th.

Phibro Animal Health Trading Up 3.1%

Phibro Animal Health stock opened at $55.48 on Wednesday. The stock has a 50-day moving average price of $48.15 and a 200 day moving average price of $43.04. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 24.66, a price-to-earnings-growth ratio of 0.83 and a beta of 0.74. Phibro Animal Health has a 52 week low of $16.16 and a 52 week high of $56.30. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The company had revenue of $373.91 million for the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Sell-side analysts anticipate that Phibro Animal Health will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Wednesday, March 4th. Phibro Animal Health’s dividend payout ratio (DPR) is 21.33%.

Insiders Place Their Bets

In related news, CEO Jack Bendheim sold 110,842 shares of Phibro Animal Health stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96. Following the completion of the transaction, the chief executive officer directly owned 122,958 shares in the company, valued at approximately $5,948,708.04. This trade represents a 47.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 316,800 shares of company stock worth $15,278,569 in the last three months. 50.13% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Phibro Animal Health by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after purchasing an additional 546 shares in the last quarter. Millennium Management LLC boosted its holdings in Phibro Animal Health by 74.3% during the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after buying an additional 154,281 shares in the last quarter. Jane Street Group LLC boosted its holdings in Phibro Animal Health by 65.3% during the first quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock worth $724,000 after buying an additional 13,404 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Phibro Animal Health by 97.3% during the second quarter. Envestnet Asset Management Inc. now owns 24,334 shares of the company’s stock valued at $621,000 after buying an additional 11,999 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Phibro Animal Health by 0.3% during the second quarter. Bank of New York Mellon Corp now owns 268,877 shares of the company’s stock valued at $6,867,000 after buying an additional 906 shares during the period. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.